Liraglutide 3.0 mg Reduces All Body Regions but Preserves Relative Lean Mass Over 35 Days
Liraglutide 3.0 mg/day over 35 days reduced total, trunk, hip, and extremity mass, with slight absolute lean mass decrease but maintained relative lean mass and fat-free mass percentages.
Quick Facts
What This Study Found
Liraglutide 3.0 mg reduced body weight, BMI, total mass, and regional mass (trunk, hip, extremities) over 35 days. Absolute fat-free and lean mass decreased slightly, but relative percentages remained stable.
Key Numbers
How They Did This
Secondary analysis of a crossover RCT with 20 obese adults receiving liraglutide 3.0 mg/day or placebo for 35 days, with DXA body composition and hormone measurements.
Why This Research Matters
Distinguishing between proportional mass loss and selective muscle wasting is crucial for understanding GLP-1 drug safety regarding body composition.
The Bigger Picture
The proportional mass loss pattern suggests GLP-1 drugs cause an overall "downsizing" rather than selective muscle destruction — a more reassuring interpretation.
What This Study Doesn't Tell Us
Short duration (35 days). Small sample. Secondary analysis. Long-term composition changes may differ as fat stores deplete.
Questions This Raises
- ?Will proportional loss continue long-term, or will lean mass eventually decline disproportionately?
- ?Does resistance exercise shift the ratio toward more fat loss?
- ?Are there biomarkers predicting who will lose more lean mass?
Trust & Context
- Key Stat:
- Relative lean preserved Despite absolute mass loss everywhere, lean and fat-free mass percentages remained stable — proportional shrinkage, not muscle wasting
- Evidence Grade:
- Secondary analysis of crossover RCT. Important body composition data but short-term and small sample.
- Study Age:
- Published in 2025.
- Original Title:
- Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
- Published In:
- Diabetes research and clinical practice, 233, 113113 (2026)
- Authors:
- Gutierrez de Piñeres, Valeria(2), Ramirez-Cisneros, Arantxa(2), Tamayo-Torres, Claudia S(2), Angelidi, Angeliki M, Kavelidou, Marianthi, Stefanakis, Konstantinos, Mantzoros, Christos S
- Database ID:
- RPEP-15245
Evidence Hierarchy
Frequently Asked Questions
Does high-dose liraglutide cause muscle loss?
In absolute terms, lean mass decreased slightly over 35 days. However, the percentage of lean mass stayed the same — meaning the body lost fat and muscle proportionally. It is shrinking overall, not selectively losing muscle.
Should I worry about muscle on Saxenda?
Early data suggests proportional loss, which is reassuring. However, resistance exercise and adequate protein are still recommended to shift the balance toward more fat loss and better muscle preservation.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15245APA
Gutierrez de Piñeres, Valeria; Ramirez-Cisneros, Arantxa; Tamayo-Torres, Claudia S; Angelidi, Angeliki M; Kavelidou, Marianthi; Stefanakis, Konstantinos; Mantzoros, Christos S. (2026). Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.. Diabetes research and clinical practice, 233, 113113. https://doi.org/10.1016/j.diabres.2026.113113
MLA
Gutierrez de Piñeres, Valeria, et al. "Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.." Diabetes research and clinical practice, 2026. https://doi.org/10.1016/j.diabres.2026.113113
RethinkPeptides
RethinkPeptides Research Database. "Effects of liraglutide treatment for 35-days on total and re..." RPEP-15245. Retrieved from https://rethinkpeptides.com/research/gutierrez-2026-effects-of-liraglutide-treatment-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.